3JVR

Characterization of the Chk1 allosteric inhibitor binding site


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.76 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.202 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Characterization of the CHK1 allosteric inhibitor binding site.

Vanderpool, D.Johnson, T.O.Ping, C.Bergqvist, S.Alton, G.Phonephaly, S.Rui, E.Luo, C.Deng, Y.L.Grant, S.Quenzer, T.Margosiak, S.Register, J.Brown, E.Ermolieff, J.

(2009) Biochemistry 48: 9823-9830

  • DOI: 10.1021/bi900258v
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Checkpoint kinase 1 (CHK1) is a key element in the DNA damage response pathway and plays a crucial role in the S-G(2)-phase checkpoint. Inhibiting CHK1 is a therapeutic strategy involving abrogation of the G2/M mitotic checkpoint defense of tumor cel ...

    Checkpoint kinase 1 (CHK1) is a key element in the DNA damage response pathway and plays a crucial role in the S-G(2)-phase checkpoint. Inhibiting CHK1 is a therapeutic strategy involving abrogation of the G2/M mitotic checkpoint defense of tumor cells toward lethal damage induced by DNA-directed chemotherapeutic agents. To date, most CHK1 inhibition approaches have involved targeting the ATP site of this kinase. In this study, we provide crystallographic and kinetic characterization of two small molecule inhibitors that bind to an allosteric site in the proximity of the CHK1 substrate site. Analysis of kinetic and biophysical data has led to the conclusion that these small molecule allosteric site inhibitors of CHK1 are reversible and are neither ATP- nor peptide substrate-competitive. K(i) values of 1.89 and 0.15 microM, respectively, have been determined for these compounds using a mixed inhibitor kinetic analysis. Cocrystal structures of the inhibitors bound to CHK1 reveal an allosteric site, unique to CHK1, located in the C-terminal domain and consisting of a shallow groove linked to a small hydrophobic pocket. The pocket displays induced fit characteristics in the presence of the two inhibitors. These findings establish the potential for the development of highly selective CHK1 inhibitors.


    Organizational Affiliation

    Department of Biochemistry and Primary Screening, Pfizer, La Jolla, San Diego 92121, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Serine/threonine-protein kinase Chk1
A
271Homo sapiensMutation(s): 0 
Gene Names: CHEK1 (CHK1)
EC: 2.7.11.1
Find proteins for O14757 (Homo sapiens)
Go to Gene View: CHEK1
Go to UniProtKB:  O14757
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
AGX
Query on AGX

Download SDF File 
Download CCD File 
A
(1S)-1-(1H-benzimidazol-2-yl)ethyl (3,4-dichlorophenyl)carbamate
C16 H13 Cl2 N3 O2
MVMZWHAHBIJEDT-VIFPVBQESA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
AGXKi: 1890 nM (100) BINDINGDB
AGXKi: 1890 nM BINDINGMOAD
AGXKi: 1890 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.76 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.202 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 44.763α = 90.00
b = 65.362β = 93.67
c = 57.916γ = 90.00
Software Package:
Software NamePurpose
HKL-2000data collection
CNXrefinement
CNXphasing
SCALEPACKdata scaling
HKL-2000data reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2009-09-17 
  • Released Date: 2009-10-06 
  • Deposition Author(s): Chen, P.

Revision History 

  • Version 1.0: 2009-10-06
    Type: Initial release
  • Version 1.1: 2011-07-13
    Type: Version format compliance
  • Version 1.2: 2017-06-07
    Type: Source and taxonomy